Pharmacogenetic Testing Reports: Interpreting Gene-drug Interactions and Clinical Recommendations
Über den Vortrag
Der Vortrag „Pharmacogenetic Testing Reports: Interpreting Gene-drug Interactions and Clinical Recommendations“ von Melissa Kalensky, FNP-BC, PMHNP-BC, CNE ist Bestandteil des Kurses „Hormonal and Genetic Influences in Psychopharmacology“.
Quiz zum Vortrag
Which of the following represents the three main cytochrome P450 enzymes that impact drug metabolism and psychotropic medication response?
- CYP2D6, CYP3A4, and CYP2C19
- CYP1A2, CYP2D6, and CYP3A4
- CYP2C19, CYP2C9, and CYP3A5
- CYP3A4, CYP2C9, and CYP1A2
- CYP2D6, CYP2C19, and CYP2C9
When reviewing a pharmacogenetic testing report, what is the first critical step to ensure accurate interpretation?
- Verify the patient's demographic information and sample collection details.
- Review the pharmacodynamic and pharmacokinetic implications sections.
- Analyze the smoking status for potential CYP1A2 metabolism effects.
- Identify all medications in significant gene-drug interaction category.
- Compare the patient's genetics against the standard dosing guidelines.
Dozent des Vortrages Pharmacogenetic Testing Reports: Interpreting Gene-drug Interactions and Clinical Recommendations
Melissa Kalensky, FNP-BC, PMHNP-BC, CNE
Dr. Melissa Kalensky, FNP-BC, PMHNP-BC, CNE is dual-certified as a Family Nurse Practitioner and a Psychiatric Mental Health Nurse Practitioner.
She specializes in primary care, community health, and integrated behavioral healthcare. Her expertise spans trauma-informed care and psychiatry across all age groups, from children to adults.
At Lecturio, she teaches psychopharmacology to advanced practice providers, helping to bridge the gap between psychiatric and primary care practice.
Kundenrezensionen
5,0 von 5 Sternen
| 5 Sterne |
|
5 |
| 4 Sterne |
|
0 |
| 3 Sterne |
|
0 |
| 2 Sterne |
|
0 |
| 1 Stern |
|
0 |
